ArticleAnnals of the rheumatic diseases2004
Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.
Article in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Successful Development of Nonclinical Anti-Drug Antibody Assays to Support Zinpentraxin Alfa Reproductive Toxicology Studies.The AAPS journal · 2024Article
- Article
- Complementary Roles of Short and Long Pentraxins in the Complement-Mediated Immune Response toFrontiers in immunology · 2021Review
- The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling.Journal of hepatology · 2016Review
- Contribution of bone marrow-derived fibrocytes to liver fibrosis.Hepatobiliary surgery and nutrition · 2015Review
- Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis.Molecular & cellular proteomics : MCP · 2012Article
- Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors.Current opinion in organ transplantation · 2011Review
- Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins (TRAP) in human plasma.Analytical chemistry · 2010Article
- Serum markers may distinguish biliary atresia from other forms of neonatal cholestasis.Journal of pediatric gastroenterology and nutrition · 2010Article
- Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo.Science translational medicine · 2009Article
- Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients.Clinical rheumatology · 2007Article
- Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.Annals of the rheumatic diseases · 2005Article
- Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins.Journal of clinical lipidologyArticle
- A serum amyloid P-binding hydrogel speeds healing of partial thickness wounds in pigs.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum amyloid P component (SAP) and acute phase proteins like C-reactive protein contribute to the clearance of apoptotic cells. This response is diminished in systemic lupus erythematosus (SLE).
objectivesTo analyse SAP concentrations in SLE in relation to disease activity, and investigate whether SAP reacts like an acute phase protein.
methodsSAP was measured in 40 patients with SLE during active and inactive disease and compared with healthy controls and patients with rheumatoid arthritis and Wegener's granulomatosis. Normal SAP values were determined in 120 healthy controls by ELISA. C reactive protein and serum amyloid A (SAA) were measured in all subjects and their levels related to SAP. SAP was also measured serially in 11 patients with breast cancer treated with recombinant human interleukin-6, and in 16 patients with sepsis.
resultsIn SLE, SAP was unaltered compared with healthy controls and was not influenced by disease activity, in contrast to C reactive protein and SAA, which increased during active disease. SAP increased in Wegener's granulomatosis but not in rheumatoid arthritis. The rise in C reactive protein and SAA was most pronounced in Wegener's granulomatosis with active disease. SAP did not change significantly during an acute phase response. No correlation was found between SAP and C reactive protein or SAA, but there was a correlation between SAA and C reactive protein (r = 0.4989, p = 0.0492).
conclusionsPatients with SLE have normal circulating SAP levels. In contrast to C reactive protein or SAA, SAP does not act as an acute phase protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.